C. G. Langdon

发表

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.

M. Held, C. G. Langdon, J. Platt, 2013, Cancer discovery.

PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.

K. Brown, R. Halaban, M. Davies, 2015, Cancer research.

The perfect PTEN – transcriptional regulation by PTEN dictates sarcoma identity

C. G. Langdon, M. Hatley, 2021, Molecular & Cellular Oncology.

Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.

C. G. Langdon, 1991, American heart journal.

Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma.

C. G. Langdon, A. Drollmann, M. Alexander, 2005, Respiratory medicine.

Evaluation of a Breath Operated Powder Inhaler

C. G. Langdon, G. Pover, S. Jones, 1988, The Journal of international medical research.

A Multicentre Study of Tenoxicam for the Treatment of Osteo-Arthritis and Rheumatoid Arthritis in General Practice

C. G. Langdon, V. Jamieson, S. A. Hill, 1990, The Journal of international medical research.

Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer

R. Means, C. G. Langdon, M. Bosenberg, 2018, Pigment cell & melanoma research.

Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity

P. Leavey, J. Rehg, D. Finkelstein, 2021, Nature Communications.

Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models

Shaomeng Wang, C. G. Langdon, J. Platt, 2014 .

The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitors

R. Mamillapalli, C. G. Langdon, J. Platt, 2015, Pigment cell & melanoma research.

Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor

J. Koo, R. Means, R. Mamillapalli, 2017, Molecular Cancer Therapeutics.

Nuclear PTEN’s Functions in Suppressing Tumorigenesis: Implications for Rare Cancers

C. G. Langdon, 2023, Biomolecules.

Genetic context of oncogenic drivers dictates vascular sarcoma development in aP2‐Cre mice

J. Rehg, D. Finkelstein, C. G. Langdon, 2022, The Journal of pathology.

Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma.

C. G. Langdon, U. Tollemar, P. D. Richardson, 1994, Respiratory medicine.

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Christos Hatzis, Lajos Pusztai, Bilge Aktas, 2017, Cancer research.

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells

Shaomeng Wang, R. Mamillapalli, C. G. Langdon, 2015, Oncotarget.

Efficacy and acceptability of fusidic acid cream and mupirocin ointment in acute skin sepsis

C. G. Langdon, K. Mahapatra, 1990 .

p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.

R. Means, C. G. Langdon, M. Bosenberg, 2017, The Journal of investigative dermatology.

Efficacy and tolerability of diclofenac dispersible in elderly patients with osteoarthritis.

C. G. Langdon, R. Bakshi, H. Rotman, 1991, Current medical research and opinion.

A Multicenter Comparison of Carvedilol with Hydrochlorothiazide in the Treatment of Mild‐to-Moderate Essential Hypertension

C. G. Langdon, P. H. Young, G. Baxter, 1991, Journal of cardiovascular pharmacology.